inspection – Pharma GMP

Stability vs Hold Time: What Inspectors Expect You to Show

digi — Wed, 26 Nov 2025 04:00:04 +0000

Stability vs Hold Time: What Inspectors Expect You to Show Understanding Stability Data and Hold Time Studies for Bulk Product: A Step-by-Step Guide for Compliance In pharmaceutical manufacturing, ensuring product quality throughout production processes is paramount. Among the critical quality considerations are the concepts of stability data and hold time studies for bulk product. These...

How to Present Your Process Control Strategy in Regulatory Inspections

digi — Wed, 26 Nov 2025 03:54:04 +0000

How to Present Your Process Control Strategy in Regulatory Inspections Effective Presentation of Your Process Control Strategy in Pharmaceutical Manufacturing Inspections The process control strategy in pharmaceutical manufacturing is a critical element in assuring product quality, compliance, and patient safety. Regulatory authorities in the US, UK, and EU increasingly expect a clear, scientifically justified, and...

Inspection Cases: Cross Contamination Deficiencies and Lessons Learned

digi — Wed, 26 Nov 2025 01:18:04 +0000

Inspection Cases: Cross Contamination Deficiencies and Lessons Learned Inspection Cases: Cross Contamination Deficiencies and Lessons Learned Cross contamination prevention in manufacturing is a fundamental pillar of pharmaceutical Good Manufacturing Practice (GMP). Strict control of cross contamination is essential to assure patient safety, product quality, and regulatory compliance in the pharmaceutical industry. Despite comprehensive regulations and...

Inspection Findings on Weak Change Control and Unauthorised Modifications

digi — Tue, 25 Nov 2025 20:03:04 +0000

Inspection Findings on Weak Change Control and Unauthorised Modifications Addressing Weak Change Control and Unauthorised Modifications: A Step-by-Step GMP Tutorial In the pharmaceutical industry, robust change control systems are essential to maintaining product quality, patient safety, and regulatory compliance. However, regulatory inspections frequently uncover deficiencies such as unauthorized changes, poor impact assessment, and missing records,...

Inspection Findings on Weak Training and Competency Programs

digi — Tue, 25 Nov 2025 19:42:04 +0000

Inspection Findings on Weak Training and Competency Programs Step-by-Step Guide to Addressing Training and Competency Inspection Findings in Pharmaceutical GMP Training and competency are foundational elements of a compliant pharmaceutical manufacturing environment. Regulatory agencies such as the FDA, EMA, MHRA, PIC/S, and WHO routinely identify deficiencies related to training programs during GMP inspections. These training...

Inspection Findings on Poor Documentation Practices in Pharma Sites

digi — Tue, 25 Nov 2025 18:57:04 +0000

Inspection Findings on Poor Documentation Practices in Pharma Sites Inspection Findings on Poor Documentation Practices in Pharmaceutical Manufacturing Sites Accurate and reliable documentation is the cornerstone of compliance in pharmaceutical manufacturing. Regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global agencies consistently emphasize the criticality...

Inspection Findings on Weak Deviation and CAPA Management in Manufacturing

digi — Tue, 25 Nov 2025 17:48:04 +0000

Inspection Findings on Weak Deviation and CAPA Management in Manufacturing Effective Management of Manufacturing Deviations and CAPA: Addressing Weaknesses Identified in Inspections Manufacturing deviations and CAPA management remain critical focal points during regulatory inspections conducted by FDA, EMA, MHRA, and other global authorities. Repeated inspection findings highlight systemic weaknesses such as weak CAPA, repeat deviations,...

Inspection Cases: Reprocessing Practices That Led to Enforcement Actions

digi — Tue, 25 Nov 2025 17:45:04 +0000

Inspection Cases: Reprocessing Practices That Led to Enforcement Actions Inspection Cases: Step-by-Step Guide to Understanding Rework and Reprocessing of Batches in GMP Pharmaceutical manufacturing demands stringent adherence to Good Manufacturing Practice (GMP) regulations to ensure product quality, safety, and efficacy. Among the critical aspects governed under GMP is the rework and reprocessing of batches. Improper...

Inspection Findings on Inadequate Visual Inspection Programs

digi — Tue, 25 Nov 2025 17:09:04 +0000

Inspection Findings on Inadequate Visual Inspection Programs Comprehensive Step-by-Step Guide to Visual Inspection of Injectables GMP Requirements Visual inspection of parenteral products is a critical control point in pharmaceutical manufacturing to ensure product quality and patient safety. Manufacturers must comply with strict visual inspection of injectables GMP requirements to detect defects such as particulates, container...

Inspection Findings on Poor Control of Capsule Filling Processes

digi — Tue, 25 Nov 2025 16:27:04 +0000

Inspection Findings on Poor Control of Capsule Filling Processes Comprehensive Step-by-Step Guide on Capsule Filling Controls and In Process Checks Pharmaceutical manufacturing requires rigorous adherence to Good Manufacturing Practices (GMP) to ensure product quality and patient safety. Capsule filling controls and in process checks are critical components of the capsule manufacturing process that directly influence...